FDA Rejects Promising Cancer Drug Developed in China
(MedPage Today) -- The FDA declined to approve a closely watched drug developed in China for an indication in non-small cell lung cancer (NSCLC), drugmaker Summit Therapeutics announced, though the investigational bispecific antibody could soon...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.